Vasily Fedorin

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI.

Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD.

MTS Bank PJSC provides retail and corporate banking services. It offers account opening and maintenance, debit and credit cards, deposits, loans and mortgage, payroll projects, safekeeping of valuables, trade finance, money transfers, foreign exchange, acquiring, treasury, as well as settlement and cash operations. The company was founded by Vladimir Petrovich Evtushenkov, Vitaliy Semenovich Gurfinkel, Anatoliy Ivanovich Yarochkin, Stanislav Kemalyevich Arbiyev, and Valeriy Viktorovich Kryukov on October 22, 1992 and is headquartered in Moscow, Russia.

Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom.

Part of Mobile TeleSystems PJSC, MGTS Finance SA operates as an acquisition vehicle that was created by Comstar United TeleSystems OJSC to acquire Svyazinvest JSC.

Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA.

UltraSoC Technologies Ltd. engages in the development of debugging technology for the embedded electronic systems. It offers semiconductor IP for on-chip analytics, performance optimization, and hardware-based security. The company was founded by Stephen Karl Heeks, Andrew Brian Thomas Hopkins, and Klaus Dieter McDonald-Maier in 2006 and is headquartered in Cambridge, the United Kingdom.

LesInvest LLC engages in the manufacture of sack paper and paper sacks. Its products include birch plywood, sawn timber, glued timber, wood particle boards, dendrochemistry products, and briquettes. The company was founded in 2014 and is headquartered in Petrozavodsk, Russian Federation.

Enso Ventures Ltd (Enso Ventures) is an independent venture capital firm founded in 2010 by Nikolay Danilov. The firm is headquartered in London, United Kingdom.

STEPPE Agroholding JSC engages in the production and trading of agricultural products. It operates through the following business segments: Dairy Farming, RZ Agro Holding, Sales & Trading, and Vegetable Growing. The company was founded on May 6, 2014 and is headquartered in Rostov-on-Don, Russia.

SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.

Detego Ltd. develops and distributes innovative software products for the fashion retail industry. Its products include Detego Suite, Detego InWarehousem Detego InStore, Detego InChannels, and Detego InReports. The company was founded in 2011 and is headquartered in London, the United Kingdom.

Steppe Ao provides management and business consulting services. The company was founded in 2015 by Andrej Neduzhko and is headquartered in Rostov-on-Don, Russian Federation.

Management Co. Segezha Group LLC engages in the provision of paper sack and filling solutions. The firm offers sack paper, paper sacks and bag, sawn timber, wood particles boards, artificial parchment, and birch plywood. It operates through the Paper and Packaging; and Plywood and Boards segments. The company is headquartered in Moscow, Russia.

Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY.

ACOLIN Fund Services AG engages in the distribution of domestic and foreign collective investment schemes. It also offers financial products and consulting services. The company was founded on January 31, 2018 and is headquartered in Zurich, Switzerland.

Starta Capital LLC is a Venture Capital firm is founded in 2011 by Alexey Girin and Sergey Vasiliev. The firm is headquartered in New York with additional office in Moscow.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.

Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases.

Hornet Therapeutics Ltd. provides immune cell metabolism and cell therapy for cancer treatment. The company is based in London, UK and was founded in 2019.

Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation.

Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions.

Disruptive Capital Finance LLP (Disruptive Capital) is a private equity firm founded in 2006 by Cédriane Marie de Boucaud Truell, Edmund George Truell and Roger Le Tissiermr. The firm is headquartered in London.